Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Should You Buy?

Posted by Geri Gentry on Jul 6th, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) shares saw strong trading volume on Monday . Approximately 5,275 shares traded hands during trading, a decline of 25% from the previous session’s volume of 6,988 shares.The stock last traded at $18.90 and had previously closed at $18.50.

Analyst Ratings Changes

A number of research analysts have weighed in on AAPG shares. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective for the company. BTIG Research reissued a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $46.43.

Check Out Our Latest Research Report on Ascentage Pharma Group International

Ascentage Pharma Group International Trading Up 3.2%

The firm has a 50-day moving average of $19.37 and a 200 day moving average of $23.25. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter valued at $383,000. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. XY Capital Ltd boosted its position in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.